OrbiMed is a healthcare-focused investment firm based in New York City, established in 1989. The firm specializes in providing a range of financing solutions, including bridge loans, senior debt, and structured debt capital for both commercial-stage public and private healthcare companies. OrbiMed invests across various sectors within the healthcare industry, such as pharmaceuticals, life sciences, digital health, medical devices, biopharmaceuticals, diagnostics, healthcare technology, and biotechnology. With approximately $5 billion in assets under management, OrbiMed aims to support a spectrum of healthcare companies, from early-stage ventures to established multinational corporations.
601 Lexington Avenue (at 53rd Street), 54th Floor New York, NY 10022-4629
1700 Owens Street Suite 540 San Francisco, CA 94158
Suite F 27, Grand Hyatt Plaza Santacruz (East) Mumbai, 400055, India
89 Medinat HaYehudim St Building E, 11th Floor Herzliya 4614001, Israel
Unit 4706, Raffles City Shanghai Office Tower 268 Xizang Middle Road Shanghai 200001, P.R. China
12/F International Commerce Centre 1 Austin Road West, Unit 01 Kowloon, Hong Kong
Roy Amariglio Ph.D
Principal
Mona Ashiya
Private Equity Partner
David Bonita
General Partner
Sven Borho
Partner
Evan Caplan
Principal
Sumona Chakraborty
Director
Dina Chaya
Partner, Private Equity
Nissim Darvish
Venture Partner
Michael Eggenberg
Managing Director
Lars Enstrom
Managing Director
Joshua Golomb
Partner, Public Equity
Geoffrey Hsu
General Partner
Alexandria Huynh Ph.D
Analyst
Mark R. Jelley
Partner, Credit and Royalty
Kip Kitur Ph.D
Vice President, Private Equity
Dimitri Krainc
Venture Partner
Jonathan Lee
Partner
Yifu Liu
Managing Director, Asia
Jonathan Mandelbaum
Vice President, Private Equity
St John Donnie McGrath
Venture Partner
Anat Naschitz
Venture Partner
W. Carter Neild
Managing Partner
Valerie Odegard
Venture Partner
Topher Orr
Partner, Public Equity
Trevor M. Polischuk
Public Equity Partner
Matthew S. Rizzo
General Partner
William Sawyer
Public Equity Partner
Michael B. Sheffery
Partner and Co-Founder
Natasha Shervani
Vice President
Jonathan Silverstein
Executive Partner
Vivek Sivathanu Ph.D
Vice President, Private Equity
Charles Steinman
Analyst
C. Scotland Stevens
General Partner
Clive Wang
Associate
David Wang
Partner and Senior Managing Director, Asia
Iris Wang
Partner
Steven Wang
Partner
Dimitrios Weedon
Managing Director
Matthew L. Wotiz
Principal
Stella Xing
Managing Director
Diyong Xu
Principal, Private Equity
Nate Yee
Principal
Jessica Zhang Ph.D
Senior Associate
Daniel Zhou
Managing Director, Asia
Guowei Wang Ph.D
Senior Managing Director, Asia and Partner
Past deals in Pennsylvania
Pinnacle Medicines
Series A in 2024
Pinnacle Medicines is a peptide drug discovery company located in Doylestown, Pennsylvania. The company specializes in developing peptide-based therapeutics to address unmet medical needs. Utilizing AI-driven drug design tools, Pinnacle Medicines focuses on creating safe and effective treatments for medical applications. Through its innovative approach, the company aims to enhance the availability of convenient and reliable therapeutics for various health challenges.
Scout Bio
Series B in 2021
Scout Bio, Inc. is a biotechnology company focused on developing innovative therapies for chronic health conditions in pets, utilizing veterinary biotechnology and gene therapy. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating one-time treatments to address significant issues such as anemia linked to chronic kidney disease in cats. Scout Bio employs Adeno-associated viral vector technology to design and deliver protein and monoclonal antibody therapeutics through single intra-muscular injections. The company's mission is to apply advancements from human medicine to improve veterinary care and enhance the quality of life for pets.
Century Therapeutics
Series C in 2021
Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.
Harmony Biosciences
Debt Financing in 2020
Harmony Biosciences, established in 2017 and based in Plymouth Meeting, Pennsylvania, is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare neurological disorders. Its primary product, WAKIX (pitolisant), is a first-in-class medication designed to increase histamine signaling in the brain, approved for treating cataplexy in adult narcolepsy patients. Harmony Biosciences operates as a subsidiary of Harmony Biosciences Holdings, Inc., which is dedicated to addressing unmet medical needs in this therapeutic area.
Passage Bio
Series B in 2019
Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.
Passage Bio
Series A in 2019
Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.
TELA Bio
Private Equity Round in 2017
TELA Bio, Inc. is a medical technology company based in Malvern, Pennsylvania, established in 2012. The company specializes in the design, development, and marketing of tissue reinforcement materials aimed at addressing unmet needs in soft tissue reconstruction. TELA Bio offers a range of products, including the OviTex Reinforced Tissue Matrix, which is utilized in hernia repair and abdominal wall reconstruction, and the OviTex PRS Reinforced Tissue Matrix, designed for plastic and reconstructive surgery. Additionally, TELA Bio provides OviTex products specifically for laparoscopic and robotic-assisted surgical procedures, which are derived from ovine rumen and incorporate polypropylene fiber. The company's marketing efforts are primarily focused in the United States, utilizing a direct sales force to promote its innovative solutions in soft tissue repair.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.